Wadenberg M L, Ahlenius S
Department of Psychology, University of Stockholm, Sweden.
J Neural Transm Gen Sect. 1991;83(1-2):43-53. doi: 10.1007/BF01244451.
The administration of the 5-HT1A agonist 8-OH-DPAT, 0.1 mg kg-1 sc-20 min, produced a moderate suppression of conditioned avoidance behavior (60% of controls) in the rat. This effect, however, was not seen after administration of higher doses, 0.4 and 1.6 mg kg-1 sc. The number of intertrial crosses were not affected by the lower dose but significantly increased by administration of the two higher doses of 8-OH-DPAT. The dopamine D2 receptor blocking agent raclopride, 0.05 mg kg-1, by itself did not suppress the avoidance behavior, but in combination with 8-OH-DPAT produced suppression of avoidance behavior (30% of controls) as well as intertrial crosses. Open field locomotor activity was suppressed by raclopride, 0.1 mg kg-1 sc, or by 8-OH-DPAT, 0.1 mg kg-1 sc. The combined treatment produced a further suppression of locomotor activity and a marked increase in "immobility" (stationary movements). Treadmill locomotion, however, was not affected by either compound by itself, whereas the combined treatment impaired treadmill performance. Suppression of treadmill performance by a higher dose of raclopride, 0.4 mg kg-1 sc, was not altered by the additional treatment with 8-OH-DPAT, 0.1 mg kg-1. In contrast to the additive effects of 8-OH-DPAT and raclopride on conditioned avoidance behavior, open field locomotion and treadmill performance, the catalepsy produced by raclopride, 16 mg kg-1 was completely antagonised by treatment with 8-OH-DPAT 0.1 mg kg-1. Taken together, the present findings demonstrate strong interactions between a 5-HT agonist and a DA D2 antagonist on some critical tests for antipsychotic-like actions and extrapyramidal motor effects in rats, and suggest new possibilities in the search for new antipsychotic drugs with higher clinical efficacy and less extrapyramidal side effects.
皮下注射5 - 羟色胺1A受体激动剂8 - 羟基 - 二丙基氨基四氢萘(8 - OH - DPAT),剂量为0.1毫克/千克,注射后20分钟,大鼠的条件性回避行为受到中度抑制(为对照组的60%)。然而,注射较高剂量(0.4毫克/千克和1.6毫克/千克,皮下注射)后未观察到这种效应。较低剂量的8 - OH - DPAT对试验间隔期的穿越次数没有影响,但注射两个较高剂量的8 - OH - DPAT后,穿越次数显著增加。多巴胺D2受体阻断剂雷氯必利,剂量为0.05毫克/千克,单独使用时不会抑制回避行为,但与8 - OH - DPAT联合使用时会抑制回避行为(为对照组的30%)以及试验间隔期的穿越次数。皮下注射0.1毫克/千克的雷氯必利或0.1毫克/千克的8 - OH - DPAT会抑制旷场运动活性。联合治疗进一步抑制了运动活性,并显著增加了“不动”(静止动作)。然而,跑步机运动不受任何一种化合物单独影响,而联合治疗会损害跑步机运动表现。皮下注射较高剂量(0.4毫克/千克)的雷氯必利对跑步机运动表现的抑制作用,不会因额外注射0.1毫克/千克的8 - OH - DPAT而改变。与8 - OH - DPAT和雷氯必利对条件性回避行为、旷场运动和跑步机运动表现的相加效应相反,16毫克/千克的雷氯必利所致的僵住症会被0.1毫克/千克的8 - OH - DPAT治疗完全拮抗。综上所述,目前的研究结果表明,在大鼠抗精神病样作用和锥体外系运动效应的一些关键试验中,5 - 羟色胺激动剂和多巴胺D2拮抗剂之间存在强烈相互作用,并为寻找具有更高临床疗效和更少锥体外系副作用的新型抗精神病药物提供了新的可能性。